V)>$$C~C-D}3&TD8/>H[F|5|ZVG}LW
SYSTEM PROCESSING...
V)>$$C~C-D}3&TD8/>H[F|5|ZVG}LW
SYSTEM PROCESSING...
Posted: 2025-05-13 06:14:29 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-13 06:20:47 UTC
Verified By
Rollup News
The FDA is exploring the use of AI, including a potential system called 'cderGPT' developed by OpenAI, to expedite the drug review process. The agency has already conducted its first AI-assisted review, aiming to significantly reduce approval timelines, despite concerns about AI inaccuracies. This initiative is led by the FDA's new AI officer and a tech task force, signaling a move towards integrating AI in modern medicine.
Potential to speed up drug review process
First AI-assisted scientific review conducted
Collaboration between FDA and OpenAI
AI hallucinations and inaccuracies
Potential opposition to replacing traditional review processes